Trial Profile

Clinical phase III study of YP-18 for febrile neutropenia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Piperacillin/tazobactam (Primary)
Indications Febrile neutropenia
Focus Therapeutic Use
Sponsors Taiho Pharmaceutical

Most Recent Events

30 Jun 2015 New trial record
26 Jun 2015 As per a Taiho Pharmaceutical media release, this trial is one of the pivotal trials on which the MHLW Japan approval of piperacillin/tazobactam for use in Febrile Neutropenia is based upon.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com